UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.

abstract：PURPOSE:To investigate the effect of the antihistamine ketotifen on multidrug resistance in human breast cancer cells and doxorubicin toxicity in mice. METHODS:Clonogenicity assays were used to test the effect of ketotifen on human multidrug resistant breast cancer cell lines exposed to chemotherapeutic agents. Flow c...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Y,Berger SA

更新日期：2003-05-01 00:00:00

abstract：PURPOSE:Methotrexate polyglutamates (MTXpg) facilitate incorporation of thioguanine nucleotides into DNA (DNA-TG, the primary cytotoxic thiopurine metabolite and outcome determinant in MTX/6-mercaptopurine treatment of childhood ALL). We hypothesized that mapping erythrocyte levels of MTXpg with 1-6 glutamates and thei...

journal_title：Cancer chemotherapy and pharmacology

authors： Nersting J,Nielsen SN,Grell K,Paerregaard M,Abrahamsson J,Lund B,Jonsson OG,Pruunsild K,Vaitkeviciene G,Kanerva J,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

更新日期：2019-01-01 00:00:00

abstract：:Macroautophagy is widely accepted as a cytoprotective mechanism against various environmental stresses. While inhibition of autophagy is generally considered to increase the susceptibility of cancer cells to therapeutic agents, whether it also plays a similar role in tumor stem cells is unclear and still controversial...

journal_title：Cancer chemotherapy and pharmacology

authors： Lin YH,Huang YC,Chen LH,Chu PM

更新日期：2015-05-01 00:00:00

abstract：:Anticipating the renewed clinical trial of the antitumor agent 2-amino-1,3,4-thiadiazole (AT, NSC-4728), we have studied the pharmacologic fate of AT-5-14C in beagle dogs. The drug was only minimally metabolized in 5 h; the radioactivities in the urine, and particularly in the plasma, resided almost entirely in unchan...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu K,Loo TL

更新日期：1980-01-01 00:00:00

abstract：:Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic...

journal_title：Cancer chemotherapy and pharmacology

authors： Saban N,Bujak M

更新日期：2009-07-01 00:00:00

abstract：:Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumoral activity. Our group has shown that MB was capable of inhibiting the in vitro growth of erythroleukemic cells with multidrug resistance (MDR). However, there are no studies comparing the cytotoxicity of this molecule for ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kirszberg C,Rumjanek VM,Capella MA

更新日期：2005-12-01 00:00:00

abstract：:Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and ce...

journal_title：Cancer chemotherapy and pharmacology

authors： Bogush T,Smirnova G,Shubina I,Syrkin A,Robert J

更新日期：1995-01-01 00:00:00

abstract：:Anthracyclines are important antitumor agents used in the treatment of solid tumors, lymphomas, and acute lymphoblastic as well as myelocytic leukemias. The clinical utility of agents such as doxorubicin and daunorubicin and their well-characterized cardiotoxicity have prompted many efforts to develop analogs that ret...

journal_title：Cancer chemotherapy and pharmacology

authors： Kuffel MJ,Reid JM,Ames MM

更新日期：1992-01-01 00:00:00

abstract：:We used a microdialysis technique to determine tissue methotrexate (MTX) levels during steady state in a rodent model. Two different approaches were employed to measure the actual extracellular MTX concentrations in muscle, liver, and kidney tissues of anesthetized Wistar rats. With the reduced-perfusion-rate techniqu...

journal_title：Cancer chemotherapy and pharmacology

authors： Ekstrøm PO,Andersen A,Warren DJ,Giercksky KE,Slørdal L

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00

abstract：:Exposure of cells of the K-562 erythroleukemia cell line to 4-hydroperoxycyclophosphamide (4-HC), an analog of activated cyclophosphamide, causes a concentration-dependent inhibition of in vitro colony formation by these cells. For investigation of the role of glutathione (GSH) in the metabolism of 4-HC, GSH levels of...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters RH,Ballard K,Oatis JE,Jollow DJ,Stuart RK

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:The safety of S-1 in recurrent colorectal cancer patients with chronic myeloid leukemia (CML) treated with dasatinib has not been established. We evaluated the safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with CML treated with dasatinib. PATIENT:A 70-year-old man had undergone surgery...

journal_title：Cancer chemotherapy and pharmacology

authors： Sueda T,Kudo T,Sakai D,Uemura M,Nishimura J,Hata T,Takemasa I,Mizushima T,Yamamoto H,Ezoe S,Matsumoto K,Doki Y,Mori M,Satoh T

更新日期：2014-12-01 00:00:00

abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Firvida JL,Castro J,Madroñal C,Rodríguez-Jaráiz A,Salgado M,Belda-Iniesta C,Casado E,García-Mata J,González-Barón M,Oncopaz Cooperative Group.

更新日期：2009-02-01 00:00:00

abstract：:Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kralovanszky J,Prajda N,Kerpel-Fronius S,Bagrij T,Kiss E,Peters GJ

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

journal_title：Cancer chemotherapy and pharmacology

authors： Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

更新日期：2016-05-01 00:00:00

abstract：PURPOSE:The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sato Y,Hirakawa M,Ohnuma H,Takahashi M,Okamoto T,Okamoto K,Miyamoto H,Muguruma N,Furuhata T,Takemasa I,Kato J,Takayama T

更新日期：2017-12-01 00:00:00

abstract：:Thymidine (dThd) concentrations have been measured in the sera of normal subjects and solid tumor cancer patients by means of a sensitive high-pressure liquid chromatographic assay to determine whether natural and methotrexate (MTX)-induced fluctuations were large enough to alter the toxicity of MTX to marrow. The mea...

journal_title：Cancer chemotherapy and pharmacology

authors： Howell SB,Mansfield SJ,Taetle R

更新日期：1981-01-01 00:00:00

abstract：PURPOSE:The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) is approved for cancer treatment. We investigated whether gefitinib treatment can enhance human EGF (hEGF) uptake in vitro, thereby increasing the potential of hEGF as a vehicle for EGFR-targeted therapy. METHODS:W...

journal_title：Cancer chemotherapy and pharmacology

authors： He P,Li G

更新日期：2013-08-01 00:00:00

abstract：PURPOSE:The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer. METHODS:The study was a multicentric, open label, randomized, two-treatment, two-period, two-sequ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chachad S,Purandare S,Malhotra G,Naidu R

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:An intact and fully functional multiprotein DNA replication complex (DNA synthesome) from human as well as from murine mammary carcinoma cells was first isolated and characterized in our laboratory. The human cell synthesome supports the in vitro origin-specific simian virus 40 (SV40) DNA replication reaction i...

journal_title：Cancer chemotherapy and pharmacology

authors： Abdel-Aziz W,Jiang HY,Hickey RJ,Malkas LH

更新日期：2000-01-01 00:00:00

abstract：INTRODUCTION:Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment. MATERIAL AND METHODS:A retrospective review of 183 patients submitted to second-line thera...

journal_title：Cancer chemotherapy and pharmacology

authors： Reni M,Berardi R,Mambrini A,Pasetto L,Cereda S,Ferrari VD,Cascinu S,Cantore M,Mazza E,Grisanti S

更新日期：2008-09-01 00:00:00

abstract：PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the unde...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang G,Zhan Y,Wang H,Li W

更新日期：2012-03-01 00:00:00

abstract：:D-3-Azido-3-deoxy-myo-inositol (3AMI) is an inhibitor of the growth of v-sis-transformed NIH 3T3 cells but not of wild-type NIH 3T3 cells, whose effects may be mediated through the phosphatidylinositol-3'-kinase pathway. We studied some properties of the cellular pharmacology of 3AMI using high-specific-activity [3H]-...

journal_title：Cancer chemotherapy and pharmacology

authors： Brunn G,Fauq AH,Chow S,Kozikowski AP,Gallegos A,Powis G

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors. METHODS:Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either...

journal_title：Cancer chemotherapy and pharmacology

authors： Low JC,Wasan KM,Fazli L,Eberding A,Adomat H,Guns ES

更新日期：2007-11-01 00:00:00

abstract：:Schedule dependency of bisantrene was evaluated in refractory metastatic breast cancer. Patients were randomly assigned to receive either a single (S) bolus injection of 300 mg/m2 (37 patients) or an injection of 80 mg/m2 daily for 5 days (D x 5) (35 patients) every 3-4 weeks after stratification by performance status...

journal_title：Cancer chemotherapy and pharmacology

authors： Holmes FA,Esparza L,Yap HY,Buzdar AU,Blumenschein GR,Hortobagyi GN

更新日期：1986-01-01 00:00:00

abstract：OBJECTIVES:ATP-binding cassette subfamily C member 4 (ABCC4) encoding MRP4 protein is involved in pediatric acute lymphoblastic leukemia (ALL) drug resistance. The nonsynonymous single nucleotide polymorphism (SNP) rs2274407 (G912T; K304N) is located in the 3' splice acceptor site of exon 8 of ABCC4 pre-mRNA. The aim o...

journal_title：Cancer chemotherapy and pharmacology

authors： Mesrian Tanha H,Rahgozar S,Mojtabavi Naeini M

更新日期：2017-07-01 00:00:00

abstract：PURPOSE:S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC). However, systemic administration of GS is associated with a high rate of grade 3 and 4 neutropenia. Hepatic arterial infusion (HAI) of gemcitabine may overcome this problem. We conducted a prospective ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ishiwatari H,Hayashi T,Yoshida M,Ono M,Sato T,Miyanishi K,Sato Y,Takimoto R,Kobune M,Kato J

更新日期：2015-04-01 00:00:00

abstract：PURPOSE:5-Fluorouracil (5-FU), an anti-cancer drug, has been used for hepatoblastoma (HB) chemotherapy in children, who may have impaired  ovarian follicle pool reserve with lasting effects to reproduction. Therefore, this study aimed to investigate 5-FU effects on survival, growth, and morphology of ovarian preantral ...

journal_title：Cancer chemotherapy and pharmacology

authors： Almeida JZ,Lima LF,Vieira LA,Maside C,Ferreira ACA,Araújo VR,Duarte ABG,Raposo RS,Báo SN,Campello CC,Oliveira LFS,da Costa TP,Abreu JG,Figueiredo JR,Oriá RB

更新日期：2021-01-20 00:00:00

abstract：PURPOSE:Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combination with escalating doses of intermittent gefitinib (Iressa) given prior to docetaxel. METHODS:This was ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fury MG,Solit DB,Su YB,Rosen N,Sirotnak FM,Smith RP,Azzoli CG,Gomez JE,Miller VA,Kris MG,Pizzo BA,Henry R,Pfister DG,Rizvi NA

更新日期：2007-03-01 00:00:00

abstract：:Etoposide is a widely used cytotoxic drug that requires complex formulation for both the i.v. and oral preparation to ensure drug stability. Data on the stability of the i.v. formulation when diluted in infusion fluids are contradictory, and there is little information on the stability of the oral preparation in gastr...

journal_title：Cancer chemotherapy and pharmacology

authors： Joel SP,Clark PI,Slevin ML

更新日期：1995-01-01 00:00:00